JP2003522101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522101A5 JP2003522101A5 JP2000548337A JP2000548337A JP2003522101A5 JP 2003522101 A5 JP2003522101 A5 JP 2003522101A5 JP 2000548337 A JP2000548337 A JP 2000548337A JP 2000548337 A JP2000548337 A JP 2000548337A JP 2003522101 A5 JP2003522101 A5 JP 2003522101A5
- Authority
- JP
- Japan
- Prior art keywords
- naphthyridine
- formula
- alkyl
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KFAJXZVDBVRZRC-UHFFFAOYSA-N 1,5-naphthyridin-4-amine Chemical compound C1=CN=C2C(N)=CC=NC2=C1 KFAJXZVDBVRZRC-UHFFFAOYSA-N 0.000 description 1
- XQOHGKZCTXPHMB-UHFFFAOYSA-N 1,6-naphthyridin-4-amine Chemical compound C1=NC=C2C(N)=CC=NC2=C1 XQOHGKZCTXPHMB-UHFFFAOYSA-N 0.000 description 1
- PSSPSOSBJIWVGU-UHFFFAOYSA-N 2,8-dichloro-1,5-naphthyridine Chemical compound N1=CC=C(Cl)C2=NC(Cl)=CC=C21 PSSPSOSBJIWVGU-UHFFFAOYSA-N 0.000 description 1
- NWJHKNUMXALBDR-UHFFFAOYSA-N 3,8-dibromo-1,5-naphthyridine Chemical compound BrC1=CC=NC2=CC(Br)=CN=C21 NWJHKNUMXALBDR-UHFFFAOYSA-N 0.000 description 1
- BMNVIIMWNOTDPE-UHFFFAOYSA-N 3,8-dichloro-1,5-naphthyridine Chemical compound ClC1=CC=NC2=CC(Cl)=CN=C21 BMNVIIMWNOTDPE-UHFFFAOYSA-N 0.000 description 1
- FFMPVGXKIJZSQL-UHFFFAOYSA-N 4,5-dichloro-1,6-naphthyridine Chemical compound C1=NC(Cl)=C2C(Cl)=CC=NC2=C1 FFMPVGXKIJZSQL-UHFFFAOYSA-N 0.000 description 1
- DOHYGSCQVQSGBI-UHFFFAOYSA-N 4,8-dibromo-1,6-naphthyridine Chemical compound C1=NC=C2C(Br)=CC=NC2=C1Br DOHYGSCQVQSGBI-UHFFFAOYSA-N 0.000 description 1
- SQLGCTFYLAMNAC-UHFFFAOYSA-N 4,8-dichloro-1,5-naphthyridine Chemical compound C1=CN=C2C(Cl)=CC=NC2=C1Cl SQLGCTFYLAMNAC-UHFFFAOYSA-N 0.000 description 1
- RUZMWDKSPLIZSY-UHFFFAOYSA-N 4-bromo-1,5-naphthyridine Chemical compound C1=CN=C2C(Br)=CC=NC2=C1 RUZMWDKSPLIZSY-UHFFFAOYSA-N 0.000 description 1
- IQPRTBZXSSEENH-UHFFFAOYSA-N 4-bromo-1,6-naphthyridine Chemical compound C1=NC=C2C(Br)=CC=NC2=C1 IQPRTBZXSSEENH-UHFFFAOYSA-N 0.000 description 1
- JECKUINVSSXFNR-UHFFFAOYSA-N 4-chloro-1,5-naphthyridine Chemical compound C1=CN=C2C(Cl)=CC=NC2=C1 JECKUINVSSXFNR-UHFFFAOYSA-N 0.000 description 1
- GKEOOUFCVWEWHA-UHFFFAOYSA-N 4-chloro-1,6-naphthyridine Chemical compound C1=NC=C2C(Cl)=CC=NC2=C1 GKEOOUFCVWEWHA-UHFFFAOYSA-N 0.000 description 1
- GQUGYKURRVQYGU-UHFFFAOYSA-N 4-iodo-1,5-naphthyridine Chemical compound C1=CN=C2C(I)=CC=NC2=C1 GQUGYKURRVQYGU-UHFFFAOYSA-N 0.000 description 1
- 0 Bc1c(*)c(*)c(*)c(*)c1* Chemical compound Bc1c(*)c(*)c(*)c(*)c1* 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9809988.0 | 1998-05-08 | ||
| GB9809972.4 | 1998-05-08 | ||
| GBGB9809972.4A GB9809972D0 (en) | 1998-05-08 | 1998-05-08 | Compounds |
| GBGB9809988.0A GB9809988D0 (en) | 1998-05-08 | 1998-05-08 | Compounds |
| GBGB9903268.2A GB9903268D0 (en) | 1999-02-12 | 1999-02-12 | Compounds |
| GB9903268.2 | 1999-02-12 | ||
| PCT/EP1999/003100 WO1999058533A1 (en) | 1998-05-08 | 1999-05-04 | Phenylurea and phenylthio urea derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003522101A JP2003522101A (ja) | 2003-07-22 |
| JP2003522101A5 true JP2003522101A5 (https=) | 2006-02-02 |
| JP4633925B2 JP4633925B2 (ja) | 2011-02-16 |
Family
ID=27269308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548337A Expired - Fee Related JP4633925B2 (ja) | 1998-05-08 | 1999-05-04 | フェニル尿素およびフェニルチオ尿素誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6372757B1 (https=) |
| EP (1) | EP1075478B1 (https=) |
| JP (1) | JP4633925B2 (https=) |
| AU (1) | AU4037799A (https=) |
| CA (1) | CA2331735A1 (https=) |
| DE (1) | DE69906960T2 (https=) |
| ES (1) | ES2196806T3 (https=) |
| WO (1) | WO1999058533A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
| WO2000047576A1 (en) * | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| AU2548400A (en) * | 1999-02-12 | 2000-08-29 | Smithkline Beecham Plc | Novel use of orexin receptor antagonists |
| EP1144409B1 (en) * | 1999-02-12 | 2004-11-17 | SmithKline Beecham plc | Phenyl urea and phenyl thiourea derivatives |
| BRPI0109200B8 (pt) | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
| EP1288202A4 (en) * | 2000-05-11 | 2003-07-02 | Banyu Pharma Co Ltd | N-acyltetrahydroisoquinoline derivatives |
| ES2238458T3 (es) * | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | Piperidinas para uso como antagonistas de los receptores de orexina. |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| US6756379B2 (en) * | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| WO2002090355A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| CA2460051A1 (en) | 2002-07-09 | 2004-01-15 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| RU2334735C2 (ru) | 2002-10-11 | 2008-09-27 | Актелион Фармасьютиклз Лтд. | Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина |
| ES2315569T3 (es) * | 2002-12-11 | 2009-04-01 | Taro Pharmaceutical Industries Ltd. | Procedimiento de tratamiento de trastornos del movimiento usando derivados de acido barbiturico. |
| ES2297413T3 (es) | 2003-04-28 | 2008-05-01 | Actelion Pharmaceuticals Ltd. | Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina. |
| US20050032794A1 (en) * | 2003-08-05 | 2005-02-10 | Padia Janak K. | Diamine derivatives of quinone and uses thereof |
| HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| CA2557163C (en) | 2004-03-01 | 2011-08-16 | Idorsia Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| CA2572797A1 (en) * | 2004-07-02 | 2006-01-12 | Daniella Gutman | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| WO2006081522A2 (en) * | 2005-01-26 | 2006-08-03 | The Regents Of The Unversity Of California | Modulation of nmda receptor currents via orexin receptor and/or crf receptor |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2008001003A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| NZ580887A (en) | 2007-05-23 | 2012-03-30 | Merck Sharp & Dohme | Pyridyl piperidine orexin receptor antagonists |
| AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| US20110039857A1 (en) * | 2008-04-30 | 2011-02-17 | Hamed Aissaoui | Piperidine and pyroolidine compounds |
| AU2009324238A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| EP2421850A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists |
| JP2013502447A (ja) | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 |
| WO2011023585A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| CA2863413A1 (en) | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
| AU2017217931B2 (en) | 2016-02-12 | 2020-10-22 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| AU2020286381C1 (en) | 2019-06-04 | 2025-07-10 | Hager Biosciences, Llc | Imidazolo derivatives, compositions and methods as orexin antagonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0222839A4 (en) | 1985-05-17 | 1988-11-09 | Univ Australian | ANTI-MALARIA COMPOUNDS. |
| JPH05213884A (ja) | 1991-06-14 | 1993-08-24 | Upjohn Co:The | 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
| DE69633059T2 (de) | 1995-05-31 | 2005-08-18 | Sumitomo Pharmaceuticals Co., Ltd. | Neue naphthyridinderivate. |
| ATE239004T1 (de) | 1996-05-20 | 2003-05-15 | Darwin Discovery Ltd | Benzofuran carboxamide und ihre therapeutische anwendung |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
-
1999
- 1999-05-04 US US09/700,002 patent/US6372757B1/en not_active Expired - Fee Related
- 1999-05-04 EP EP99923540A patent/EP1075478B1/en not_active Expired - Lifetime
- 1999-05-04 JP JP2000548337A patent/JP4633925B2/ja not_active Expired - Fee Related
- 1999-05-04 CA CA002331735A patent/CA2331735A1/en not_active Abandoned
- 1999-05-04 ES ES99923540T patent/ES2196806T3/es not_active Expired - Lifetime
- 1999-05-04 WO PCT/EP1999/003100 patent/WO1999058533A1/en not_active Ceased
- 1999-05-04 AU AU40377/99A patent/AU4037799A/en not_active Abandoned
- 1999-05-04 DE DE69906960T patent/DE69906960T2/de not_active Expired - Lifetime